Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|March 3, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-04-2015
- Volume 11
- Issue 3
Repligen Expands US Manufacturing Facility
Author(s)Pharmaceutical Technology Editors
A facility expansion adds space for production of Repligen’s tangential flow system.
Advertisement
Repligen Corp. has completed an 11,000-sq-ft expansion of its US manufacturing facility, which includes a dedicated space for the production and assembly of the company’s Alternating Tangential Flow System
The ATF System is a product line used to increase cell density and product yield during the fermentation step of the biologic drug manufacturing process. The expansion includes areas for ATF System assembly, quality control and inventory, as well as cleanroom suites for the production of single-use ATF Systems in an ISO 7 environment.
The facility upgrade also expands on areas dedicated to cell culture research and development as well as manufacturing and support of the company's ELISA test kits and its OPUS line of pre-packed chromatography columns. An additional 7,500-sq-ft feet is reserved for future expansion of the Waltham facility.
Source:
Articles in this issue
over 11 years ago
Grand River Names Director of Manufacturingover 11 years ago
WellSpring Pharma Services Names New Presidentover 11 years ago
PBOA Supports Legislation to Protect FDA User Feesover 11 years ago
Novasep to Manufacture Celladon's Mydicar APIover 11 years ago
Modest Expectations for CMOs and Biosimilarsover 11 years ago
FDA Tightens Drug Security Regulationsover 11 years ago
Mitigating Cold-Chain Risksover 11 years ago
The Challenge of Resolving Agents for Chiral Resolutionover 11 years ago
Catalent Expands Clinical Packaging Capabilities in Europeover 11 years ago
SGS Expands Biomarker Testing Capabilities at Poitiers FacilityAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5